steady as she goes
The Company remains in dialogue with a number of pharmaceutical companies, which could lead to multiple
international licensing opportunities. Vectus continues to receive enquiries from industry participants who
recognise the significant potential of the Company’s novel anti-fibrotic compounds.
this was the most interesting statement for me...
steady as she goesThe Company remains in dialogue with a number...
Add VBS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| VBS (ASX) Chart |
Day chart unavailable